Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis.
Jason D Graci, Nina F Gnädig, Jessica E Galarraga, Christian Castro, Marco Vignuzzi, Craig E Cameron

To cite this version:
Mutational Robustness of an RNA Virus Influences Sensitivity to Lethal Mutagenesis

Jason D. Graci,a,* Nina F. Gnädig,b Jessica E. Galarraga,a Christian Castro,a Marco Vignuzzi,b and Craig E. Cameron,a

Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania, USA,a and Institut Pasteur, Viral Populations and Pathogenesis, CNRS URA 3015, Paris, Franceb

The ability to extinguish a viral population of fixed reproductive capacity by causing small changes in the mutation rate is referred to as lethal mutagenesis and is a corollary of population genetics theory. Here we show that coxsackievirus B3 (CVB3) exhibits reduced mutational robustness relative to poliovirus, manifesting in enhanced sensitivity of CVB3 to lethal mutagens that is dependent on the size of the viral population. We suggest that mutational robustness may be a useful measure of the sensitivity of a virus to lethal mutagenesis.

RNA virus genomes are replicated at mutation rates orders of magnitude higher than DNA genomes (10, 27) and exist as heterogeneous populations of genetically distinct yet related genomes. Attempts to define these populations have relied upon population genetics theory (5, 6, 34, 35); unfortunately, little empirical evidence exists validating these theories in vivo (30).

Population genetics theory predicts a log-linear relationship between the genomic mutation rate and the fecundity (average number of progeny generated per infectious cycle) needed to avoid extinction and defines a theoretical “extinction threshold” (6). A corollary of this theory is lethal mutagenesis, the ability to drive a viral population to extinction by increasing the error frequency (13).

A high mutation rate can negatively affect viral fitness and may drive a population to extinction. However, the deleterious effects of a high mutation rate may differ between viruses depending on their mutational robustness, i.e., the constancy of a phenotype in the face of deleterious mutations (26). A more robust population is able to minimize the deleterious effects of a high mutation rate by opting not to maximize fitness, a phenomenon termed “survival of the flattest” (35). Previous studies have suggested that the distributions of mutational effects between DNA and RNA virus genomes are similar (25). Therefore, the mutational robustness of a virus might be expected to be similar to that of closely related viruses.

We investigated the mutational robustness of two closely related enteroviruses, poliovirus (PV) and coxsackievirus B3 (CVB3), which employ similar replication strategies and genome organizations and exhibit 59% polyprotein identity (74% similarity) as shown by BLAST analysis (GenBank accession numbers Q5UEA2 and P03300). To compare the characteristics of mutational robustness of these two viruses, we examined the response of PV (Mahoney) and of CVB3 (CVB3/0) to increasing concentrations of the mutagenic nucleoside ribavirin (Fig. 1A). Infection was performed under conditions that included a low multiplicity of infection (MOI) so that the cumulative effect of increased mutation frequency could be observed over two or more replicative cycles. CVB3 was observed to be considerably more sensitive than PV to ribavirin treatment at 0.5 mM or greater. Dramatically increased sensitivity was not observed under conditions of high MOI (Fig. 1B), consistent with the deleterious effect of mutation being reversed by population size (fecundity), as predicted by population genetics theory.

Higher tolerance to mutagens could be explained by a number of mechanisms, including increased replication fidelity (8, 19, 23), increased mutational robustness (7, 26), or specific discrimination against the mutagen (29). It was possible that the low tolerance to mutation of CVB3 was caused by the presence of a lower-fidelity RNA-dependent RNA polymerase (RdRp) in terms of ribavirin incorporation, since at any given concentration of ribavirin, more mutagenesis would occur. To investigate this possibility, we purified the RdRps from both PV and CVB3 (12, 32) and each was incubated with a previously described substrate (sym/sub) and either the “correct” nucleotide or ribavirin triphosphate (RTP) (3, 15). Examination of ribavirin incorporation revealed that CVB3 RdRp incorporated ribavirin much less efficiently than PV RdRp (Fig. 2). Thus, heightened sensitivity of CVB3 to ribavirin treatment was not likely to have been due to a higher rate of genomic incorporation of ribavirin.

If CVB3 is less genetically robust than PV, this should manifest as a higher proportion of deleterious and/or lethal mutations at a given genomic mutation frequency. To test this hypothesis experimentally, we employed T7 RNA polymerase (T7 RNAP)-directed mutagenesis of viral genomes as previously described using the mutagenic pyrimidine analog P (14, 21, 22). Genomic RNA was in vitro transcribed for either PV or CVB3 under identical conditions to generate a defined number of mutations per genome (14, 16), and the specific infectivity of viral genomes was assessed by an infectious center assay (9). CVB3 showed greatly increased sensitivity when ~50 or more incorporations of P were made per genome (Fig. 3A). Notably, CVB3 had over 100-fold-lower relative...
specific infectivity than PV even when less than 1% of the genome was replaced by P. These results are consistent with CVB3 being less genetically robust than PV.

P incorporation into viral RNA may have two unique effects: (i) alteration of codon-anticodon recognition, resulting in amino acid substitutions in viral proteins, and (ii) disruptions in hydrogen-bonding networks essential for structural elements of the RNA. Thus, the deleterious effect of P monophosphate (PMP) substitution may be expressed at the level of either the RNA structure or the encoded proteins. To distinguish between these two possibilities, we employed two other nucleotide analogs, ITP and 4-thiouridine triphosphate (4-thioUTP). Both nucleotides are predicted to cause changes in hydrogen-bonding interactions important in stabilizing tertiary RNA structures while maintaining Watson-Crick pairings and therefore codon integrity (1, 24, 31).

Various concentrations of ITP and 4-thioUTP were employed during transcription of viral genomes, and specific infectivity was monitored as a function of genomic substitution (Fig. 3B and C). While both nucleotides reduced the specific infectivity of viral RNA, the responses observed for PV and CVB3 were identical. PMP substitution sufficient for a 10-fold reduction in PV-specific

FIG 1 CVB3 is more sensitive to ribavirin-induced mutagenesis than PV. HeLa S3 cells (1 × 10⁵ in 24-well plates) were pretreated with ribavirin for 1 h prior to infection with either PV or CVB3 at an MOI of 0.01 (A) or 5 (B) as previously described (17). Cells were incubated with ribavirin at the indicated concentration until all cells demonstrated a cytopathic effect or for 6 days, at which time virus was collected and titers were determined using HeLa S3 monolayers. Titers were normalized to controls infected with either virus in the absence of ribavirin. Typical titers for experiments performed at an MOI of 0.01 were 3 × 10⁶ (PV) and 2 × 10⁶ PFU/ml (CVB3) and at an MOI of 5 were 7 × 10⁷ (PV) and 4 × 10⁷ (CVB3). Data are plotted as the means and standard deviations of results determined with 3 independent samples.

FIG 2 CVB3 encodes an RdRp with higher fidelity than PV. The RdRp from either PV (left) or CVB3 (right) was incubated with sym/sub substrate and either the correct nucleotide substrate or RTP as previously described (3, 15). Panels for each nucleotide correspond to quenching at 30, 60, 120, 300, 600, or 1,800 s.

4-thiouridine triphosphate (4-thioUTP). Both nucleotides are predicted to cause changes in hydrogen-bonding interactions important in stabilizing tertiary RNA structures while maintaining Watson-Crick pairings and therefore codon integrity (1, 24, 31).
infectivity resulted in a 1,000-fold reduction in CVB3-specific infectivity (panel A; ~50 PMP incorporations per genome). However, 10-fold reductions in PV-specific infectivity induced by IMP or 4-thioUMP resulted in reductions of similar magnitude in CVB3-specific infectivity (panel B [1 mM IPT] and panel C [1:4 or greater ratio of 4-thioUTP to UTP]). Thus, our observations suggest that the protein-coding sequence, not the RNA structure, is the determinant of the increased sensitivity of CVB3 to genomic mutation.

Viruses with lower mutational robustness would be expected to exhibit increased susceptibility to lethal mutants and be more sensitive to mutation. To investigate this, we generated populations of PV and CVB3 in the presence or absence of 100 μM ribavirin. RNA was isolated from either the total (viable plus nonviable) virus population or from replication-competent virus obtained through plaque purification, and the capsid-coding region of 96 viral genomes was sequenced (4). To permit comparison with previous work, plaque-competent virus was required. The A372V Nancy strain of CVB3 was used, which differs from CVB3/0 at only 12 amino acid positions and carries an identical genome in total RNA; 0.7 versus 1.2 in plaque-purified genomes. To permit comparison of mutation distributions among codon positions, we were not surprised to find that mutations were randomly, we were not surprised to find that mutations were

<table>
<thead>
<tr>
<th>Expt conditions</th>
<th>PV Mutation frequency</th>
<th>No. (%) of NS mutations</th>
<th>CVB3 Mutation frequency</th>
<th>No. (%) of NS mutations</th>
<th>No. (%) of S mutations</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total RNA no drug</td>
<td>6.1</td>
<td>58 (64)</td>
<td>3.8</td>
<td>70 (65)</td>
<td>37 (35)</td>
<td>1.00</td>
</tr>
<tr>
<td>total RNA RBV</td>
<td>9.6</td>
<td>29 (63)</td>
<td>6.1</td>
<td>28 (67)</td>
<td>14 (34)</td>
<td>0.8242</td>
</tr>
<tr>
<td>Plaque RNA no drug</td>
<td>1.2</td>
<td>50 (70)</td>
<td>0.7</td>
<td>22 (48)</td>
<td>24 (52)</td>
<td>0.019</td>
</tr>
<tr>
<td>Plaque RNA RBV</td>
<td>4.3</td>
<td>24 (33)</td>
<td>3.8</td>
<td>14 (18)</td>
<td>62 (82)</td>
<td>0.041</td>
</tr>
</tbody>
</table>

a Mutation frequency is represented as the number of mutations per the total 10^8 nucleotides sequenced.
b The statistical significance of the results of comparisons of mutation distributions among codon positions was determined by Fisher’s two-tailed test.

These data show that both PV and CVB3 generate mutations with similar, stochastic distributions in both the presence and absence of mutagen.

We then examined plaque-purified (viable only) virus genomes for mutation profiles. Notably, 70% of the mutations in the untreated PV were nonsynonymous, suggesting a high tolerance for mutation and changes to the protein-coding sequence that did not negatively impact the fitness of these variants with respect to that of the wild type. On the other hand, over 50% of mutations in untreated CVB3 were synonymous (S), suggesting that mostly silent rather than coding mutations are well tolerated in this virus and that it is thus less mutationally robust. This bias for silent mutation was exacerbated upon ribavirin treatment (Table 1). Notably, ribavirin decreased the ratio of NS mutations to S mutations for both viruses, likely due to its property of inducing transition mutations favoring S mutations.

Differences in fecundity or specific infectivity between the viruses might impact their sensitivity to mutagenesis. Thus, to rule out these possibilities, we infected HeLa cells with either PV or CVB3 at an MOI of 0.01 with 0, 200, or 400 μM RBV. After 48 h, virion RNA was extracted, purified, and subjected to quantitative reverse transcription-PCR (qRT-PCR) to determine the total number of genomes produced. Titered samples of all were measured to determine the total number of PFU produced under each set of conditions. We then determined the specific infectivity (PFU/genome) and fecundity (genomes/cell) (Table 2). We observed that the levels of fecundity and specific infectivity of the viruses were similar in the absence of ribavirin. Upon ribavirin treatment, we observed a similar reduction in the fecundity of the viruses but a much more pronounced reduction in specific infectivity for CVB3. This supports the notion that the sensitivity of

**TABLE 1** Mutation frequency and codon substitution distribution in virus populations

**TABLE 2** Specific infectivity of CVB3 is greatly reduced compared to that of PV after ribavirin treatment

a Titer were determined by a standard plaque assay using HeLa cells.
b Numbers of virions per milliliter were determined by qRT-PCR using virion RNA and the following primers and probes: for CVB3, the forward primer was GATGGGCGTGGTGAACGATCCAAGGC, and the 3-carboxyphenoxine (FAM) probe was CGCGCGACATCCAGTG; for PV, the forward primer was CCCGACTCACACACACACACACAGT, and the FAM probe was ACCCGTCGCTCTCC.

c Statistical significance was determined by a two-tailed unpaired t test; n = 3.
CVB3 is driven by lethal mutagenesis of packaged genomes and not by a reduction in fecundity.

We have shown that CVB3 has higher polymerase fidelity and a lower basal mutation rate than PV, which is more adversely affected by genomic mutation at a given frequency, and is less tolerant of protein-coding changes. In sum, these results support the notion of lower mutational robustness for CVB3 populations compared to PV. At this time, we cannot rule out the possibility that PV and CVB3 exhibit the same deleterious mutation rate, with CVB3 exhibiting a higher lethal mutation rate. The tempo for extinction is dictated by the rate of accumulation of lethal changes. One consequence of faster extinction is a reduction in opportunities for evolution of resistance.

The biological significance of the lower robustness of CVB3 is still unknown. Maintenance of host tropism may constrain robustness by imposing selective restraints. Nonsynonymous mutations that are fitness neutral in one host or cell type may nonetheless reduce fitness in other cell types. This may explain the lower robustness of CVB3, as this virus has been implicated in the infection of numerous organs, including the heart, pancreas, and lymphocytes, as well as the central nervous system, despite its primary route of infection and transmission being the enteric system (2, 11, 18, 20, 28). Restriction of PV genetic diversity was found to greatly impact pathogenesis and tissue distribution (33), suggesting a fundamental link between mutation rate and pathology. The possibility also exists that PV has evolved higher robustness based on environmental fluctuations and/or its higher basal mutation frequency.

The suggestion that RNA viruses obey the strictures of lethal mutagenesis theory has significant implications for antiviral therapy. Subtle (<2 log) decreases in virus titer may be sufficient to reduce the population size below the limit of viability. The stringent criteria applied to the selection of antiretroviral therapeutics for clinical studies may be overkill for selection of therapeutics against classical RNA viruses. The observation that differences between closely related viruses in drug sensitivity can be attributed to differences in mutational robustness may provide an explanation for the loss or absence of efficacy of drugs in the absence of a drug-resistant target.

ACKNOWLEDGMENTS

Financial support was provided by the National Institutes of Health (grant AI053531 to C.E.C.), the American Heart Association (established investigator award 0340028N to C.E.C.), and ERC Starting grant 242719 (to M.V.).

We thank Nora Chapman and Steven Tracy (University of Nebraska Medical Center) and Kirk Knowlton (University of California, San Diego) for providing CVB3 cDNA. We thank David Loakes and Daniel Brown (MRC Laboratory of Molecular Biology) for a gift of PTP and Claus Wilke for providing CVB3 cDNA. We thank David Loakes and Daniel Brown (MRC Laboratory of Molecular Biology) for a gift of PTP and Claus Wilke for providing CVB3 cDNA. We thank David Loakes and Daniel Brown (MRC Laboratory of Molecular Biology) for a gift of PTP and Claus Wilke

REFERENCES


